Windward Bio Debuts on Nasdaq, Shares Surge 68% on IPO Day
Clinical-stage biotech Windward Bio priced its IPO at $17 per share and closed its first trading day at $28.50 on Nasdaq.
Windward Bio, a Shanghai-based clinical-stage biotechnology company backed by Qiming Venture Partners, made its public market debut on Nasdaq on November 13, 2026, trading under the ticker symbol WWB.
The company priced its initial public offering at $17.00 per share. By the close of its first trading session, the stock had climbed to $28.50, representing a gain of roughly 68 percent from the offering price — a notably strong first-day performance by recent biotech IPO standards.
Read more Portillo's Faces Securities Class Action Over Investor Losses →
Windward Bio operates in the immunology space, positioning itself among a cohort of innovative biotechs seeking capital through U.S. public markets despite a historically volatile environment for life sciences listings. The company's backer, Qiming Venture Partners, is a prominent venture capital firm with an established track record of supporting Chinese biotech and technology companies through growth and public listings.
The listing reflects continued investor appetite for early-stage immunology platforms, particularly those with clinical-stage pipelines that offer near-term data catalysts. A strong IPO pop of this magnitude can provide the company with enhanced visibility and a broader institutional shareholder base as it advances its programs.
Continue reading at All Financial Services & Investing.